Footnotes and statements below graphics cannot absolve the problems raised by misleading claims in an promotional piece, the US Food and Drug Administration told AstraZeneca PLC in a rare warning letter.
The agency’s Office of Prescription Drug Promotion cited an AstraZeneca sales aid for its chronic obstructive pulmonary disease treatment Breztri...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?